Soons P A, Schoemaker H C, Cohen A F, Breimer D D
Center for Bio-Pharmaceutical Sciences, Leiden University, The Netherlands.
J Clin Pharmacol. 1992 Apr;32(4):324-31. doi: 10.1002/j.1552-4604.1992.tb03843.x.
The intraindividual variability in pharmacokinetics and effects of oral nifedipine (10 mg), administered with 1 week intervals, was investigated in twelve young healthy subjects. The population estimate of the coefficient of intraindividual variability (CVw) in AUC of nifedipine (13%) was much smaller than the pure between-subject variability (CVb 54%). The long-term (1 1/2 year) intraindividual variability was much larger than the short-term variability. Maximum changes from baseline-values of mean blood pressure (SBP -5%, DBP -4%) and mean heart rate (HR +21%) were small. Individual maximum changes in systolic blood pressure, diastolic blood pressure, and heart rate (SBP, DBP, and HR) and areas under effect curves were highly variable (CVw 34-250%, CVb 8-88%). For most subjects a significant positive linear relation was observed between nifedipine plasma concentration and the change in HR (mean r = 0.63). The CVw in slope (106%) and intercept (685%) were even larger than the high CVb in these parameters (38% and 252%). Changes in blood pressure were not significantly related to nifedipine plasma concentrations within these healthy subjects. The small intraindividual variability in nifedipine pharmacokinetics allows crossover studies to detect pharmacokinetic relationships between nifedipine and other dihydropyridine calcium entry blockers.
在12名年轻健康受试者中,研究了口服硝苯地平(10毫克),间隔1周给药时药代动力学和效应的个体内变异性。硝苯地平AUC的个体内变异系数(CVw)的总体估计值(13%)远小于纯粹的受试者间变异性(CVb 54%)。长期(1.5年)个体内变异性远大于短期变异性。平均血压(收缩压-5%,舒张压-4%)和平均心率(心率+21%)相对于基线值的最大变化较小。收缩压、舒张压和心率(SBP、DBP和HR)的个体最大变化以及效应曲线下面积高度可变(CVw 34 - 250%,CVb 8 - 88%)。对于大多数受试者,观察到硝苯地平血浆浓度与心率变化之间存在显著的正线性关系(平均r = 0.63)。斜率(106%)和截距(685%)的CVw甚至大于这些参数中较高的CVb(分别为38%和252%)。在这些健康受试者中,血压变化与硝苯地平血浆浓度无显著相关性。硝苯地平药代动力学中较小的个体内变异性使得交叉研究能够检测硝苯地平和其他二氢吡啶类钙通道阻滞剂之间的药代动力学关系。